Journals / Turkish Journal of Medical Sciences / 2019 / Cilt: 49 - Sayı: 1

Serum endocan level and diastolic functions in the case of lead exposure

Pages
66–73
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Due to sharing a similar mechanism, a higherserum level of endocan may be a valuable laboratory clue for impaired diastolic function in this population.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aim: Lead can cause morphological and functional changes in heart, and inflammation and endothelial dysfunction invasculature.
📊
Key Findings & Data:This study investigatedthe relationship between lead exposure, endocan levels, and diastolic functions.Materials and methods: A total of 51 lead-exposed workers without a known cardiovascular disease or risk factors and 54 healthycontrols were enrolled.
💡
Conclusion & Impact:Due to sharing a similar mechanism, a higherserum level of endocan may be a valuable laboratory clue for impaired diastolic function in this population.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background/aim: Lead can cause morphological and functional changes in heart, and inflammation and endothelial dysfunction invasculature. Endocan, as a novel indicator of endothelial dysfunction, has been used for cardiovascular diseases. This study investigatedthe relationship between lead exposure, endocan levels, and diastolic functions.Materials and methods: A total of 51 lead-exposed workers without a known cardiovascular disease or risk factors and 54 healthycontrols were enrolled. All participants underwent transthoracic echocardiography. Blood lead and serum endocan levels were analyzed.Results: Baseline demographic and clinical characteristics were found to be similar between groups. Median blood lead (32 vs 1.5 µg/dL,P < 0.001) and serum endocan levels (67 vs 57.1 pg/mL, P = 0.02) were significantly higher in the lead-exposed group. Serum endocanlevel showed a positive correlation with blood lead levels (r = 0.404, P = 0.003) in lead-exposed workers. Serum endocan level was anindependent risk factor for increased E/E’ ratio (β = 0.704, P = 0.002) and left atrial volume index (β = 1.158, P = 0.011) and higher levelof lead in blood was an independent risk factor for increased E wave (β = 8.004, P = 0.022) in lead-exposed workers.Conclusion: Worsened diastolic functions may be seen in the course of lead exposure. Due to sharing a similar mechanism, a higherserum level of endocan may be a valuable laboratory clue for impaired diastolic function in this population.

🔖

Cite This Article

YILMAZ, Ö. H., ALIŞIK, M., KARAKULAK, U. N., GÜNDÜZÖZ, M., İRİTAŞ, S. B., BÜYÜKŞEKERCİ, M., TUTKUN, L., KARA, H., BAL, C. (2022). Serum endocan level and diastolic functions in the case of lead exposure. Turkish Journal of Medical Sciences, Cilt: 49 - Sayı: 1, 66–73. https://ajindex.com/articles/610006

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Jain NB, Potula V, Schwartz J, Vokonas PS, Sparrow D, Wright RO, Nie H, Hu H. Lead levels and ischemic heart disease in a prospective study of middle-aged and elderly men: the VA Normative Aging Study. Environ Health Perspect 2007; 115: 871-875
  2. Gambelunghe A, Sallsten G, Borne Y, Forsgard N, Hedblad B, Nilsson P, Fagerberg B, Engstrom G, Barregard L. Lowlevel exposure to lead, blood pressure, and hypertension in a population-based cohort. Environ Res 2016; 149: 157-163
  3. Poreba R, Gac P, Poreba M, Mazur G. Echocardiographic assessment of myocardial function in workers occupationally exposed to lead without clinically evident heart disease. Environ Toxicol Pharmacol 2013; 36: 522-528
  4. Vaziri ND. Mechanisms of lead-induced hypertension and cardiovascular disease. Am J Physiol Heart Circ Physiol 2008; 295: 454-465
  5. Sarrazin S, Adam E, Lyon M, Depontieu F, Motte V, Landolfi C, Lortat-Jacob H, Bechard D, Lassalle P, Delehedde M. Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta 2006; 1765: 25-37
  6. Aparci M, Isilak Z, Uz O, Yalcin M, Kucuk U. Endocan and endothelial dysfunction. Angiology 2015; 66: 488-489
  7. Wang XS, Yang W, Luo T, Wang JM, Jing YY. Serum endocan levels are correlated with the presence and severity of coronary artery disease in patients with hypertension. Genet Test Mol Biomarkers 2015; 19:124-127
  8. Balta S, Demirkol S, Ozturk C, Yildirim AO, Demir M, Celik T. The relation between endocan levels and subclinic atherosclerosis. Clin Appl Thromb Hemost 2016; 22: 495-496
  9. Kundi H, Balun A, Cicekcioglu H, Karayigit O, Topcuoglu C, Kilinckaya MF, Kiziltunc E, Cetin M, Ornek E. Admission endocan level may be a useful predictor for in-hospital mortality and coronary severity index in patients with STsegment elevation myocardial infarction. Angiology 2017; 68: 46-51
  10. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18: 1440- 1463
  11. Ozaki K, Toshikuni N, George J, Minato T, Matsue Y, Arisawa T, Tsutsumi M. Serum endocan